JPRN-C000000113已完成2 期
phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive disease small-cell lung cancer.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- •1) small-cell lung cancer; 2) extensive disease; 3) Eastern Cooperative Oncology Group performance status of 0 or 1; 4) age of 20 to 70 years; 5) no prior chemotherapy; 6) neither palliative radiation nor surgery within 14 days; 7) measurable lesions; 8) a life expectancy of at least two months; 9) adequate organ fanctions; and 10) written informed consent.
排除标准
- •1) symptomatic brain metastases; 2) pleural or pericardial effusion requiring drainage; 3) interstitial pneumonitis or pulmonary fibrosis; 4) active infection; 5) watery diarrhea, paralysis of the intestine, or ileus; 6) active gastric or duodenal ulcer; 7) continuous administration of steroids or non-steroidal anti-inflammatory drugs; 8) uncontrolled diabetes mellitus or angina pectoris; 9) active concomitant malignancies; 10) a history of serious drug allergy; 11) pregnancy or lactation; and 12) unsuitable for entry to the study, decided by a medical oncologist.
研究者
相似试验
招募中
2 期
Phase II Study of cisplatin plus irinotecan for large cell neuroendocrine carcinomaarge cell neuroendocrine carcinomaJPRN-UMIN000004796ational Cancer Research Center Hospital East44
招募中
不适用
A phase II study of Irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancerNeoplasmsKCT0000670Seoul National University Hospital23
已完成
不适用
Phase II trial of irinotecan plus cisplatin for pretreated patients with Ewing sarcoma and PNETpretreated Ewing sarcoma or PNETJPRN-UMIN000001529ational cancer center hospital32
已完成
3 期
A Phase III Study Comparing Irinotecan, Cisplatin and Etoposide (PEI) with Nogitecan for the Treatment of Relapsed Small-Cell Lung Cancer (JCOG0605)Sensitive relpased small-cell lung cancerJPRN-UMIN000000828Japan Clinical Oncology Group(JCOG)180
已完成
2 期
A phase II study of nedaplatin plus irinotecan for stage III/IV and EGFR mutation negative non-small cell lung cancer with high-risk factorsJPRN-UMIN000003622Kanagawa Cancer Center35